共 16 条
[1]
Hallek M(2008)Immunochemotherapy with fludarabine (F), cyclophosphamide (C) and rituximab (R) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival of previously untreated patients with advanced chronic lymphocytic leukemia Blood 112 11-undefined
[2]
Fingerle-Rowson G(2008)Genomic aberrations, VH mutation status and outcome after after fludarabine and cyclophosphamide (FC) or FC plus rituximab (FCR) in the CLL8 trial Blood 112 11-undefined
[3]
Fink AM(2008)Rituximab plus fludarabine and cyclophosphamide (R-FC) vs. FC alone in relapsed/refractory CLL: final results of REACH BO17072 trial Blood 112 11-undefined
[4]
Busch R(2008)Subcutaneous alemtuzumab (Campath) in fludarabine-refractory CLL: final results of the CLL2H trial of the GCLLSG and comprehensive analysis of prognostic markers Blood 112 11-undefined
[5]
Stilgenbauer S(undefined)undefined undefined undefined undefined-undefined
[6]
Zenz T(undefined)undefined undefined undefined undefined-undefined
[7]
Winkler D(undefined)undefined undefined undefined undefined-undefined
[8]
Bühler A(undefined)undefined undefined undefined undefined-undefined
[9]
Robak T(undefined)undefined undefined undefined undefined-undefined
[10]
Moiseev SI(undefined)undefined undefined undefined undefined-undefined